Australia markets closed

iBio Inc (0JV.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.2700-0.0040 (-1.46%)
At close: 08:02AM CEST
Full screen
Previous close0.2740
Open0.2700
Bid0.2780 x N/A
Ask0.2940 x N/A
Day's range0.2700 - 0.2700
52-week range0.2480 - 4.2725
Volume0
Avg. volume749
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

    BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023. Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from d

  • GlobeNewswire

    iBio Announces Amendment to Credit Agreement with Woodforest

    – Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and Woodforest National Bank (“Woodforest”) have entered into a sixth amendment (the “Amendment”) to their November 1, 2021 credit agreement (the “Credit Agreement”

  • GlobeNewswire

    iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

    – AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage. The anti-EGFRvII